Literature DB >> 1549071

Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis.

G R Skinner1, C Fink, J Melling, C Wiblin, B Thornton, J Hallworth, W Gardner, P McLeish, C Hartley, A Buchan.   

Abstract

Three hundred and forty-seven subjects at risk for herpes genitalis were vaccinated with Skinner vaccine, NFUAc.HSV1.(S-MRC5), and were followed for an average duration of 2 years representing a total consortship of 664.4 years. Based on survey information obtained during this consortship, there were estimated to be 3076 recurrences which summated to 3.5 years total duration of disease and comprised at least 6794 lesions; there were an estimated 51997 episodes of intercourse including at least 241 episodes of unprotected intercourse in the presence of herpetic lesions. The rate of contraction of herpes genitalis was 6 of 54 consorts (11.1%) who received one vaccination and 7 of 293 (2.4%) who received two, three of four vaccinations. There was no evidence of physical or psychological side effects from vaccination.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1549071     DOI: 10.1007/bf00191551

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  25 in total

1.  Nice work for everybody except the patient.

Authors:  G R Skinner
Journal:  Vaccine       Date:  1989-10       Impact factor: 3.641

2.  Augmentation of the neutralisation test for type 1 HSV: evidence of high representation of neutralising antibody in the adult community.

Authors:  P J Holmes; J A Hallworth; D I Stocker; G R Skinner
Journal:  Med Microbiol Immunol       Date:  1985       Impact factor: 3.402

3.  Preparation and immunogenicity of vaccine Ac NFU1 (S-) MRC towards the prevention of herpes genitalis.

Authors:  G R Skinner; C B Woodman; C E Hartley; A Buchan; A Fuller; J Durham; M Synnott; J C Clay; J Melling; C Wiblin; J Wilkins
Journal:  Br J Vener Dis       Date:  1982-12

4.  A novel glycoprotein for detection of herpes simplex virus type 1-specific antibodies.

Authors:  F K Lee; L Pereira; C Griffin; E Reid; A Nahmias
Journal:  J Virol Methods       Date:  1986-09       Impact factor: 2.014

5.  Immunogenicity of herpes simplex virus type 1 glycoproteins expressed in vaccinia virus recombinants.

Authors:  B A Blacklaws; S Krishna; A C Minson; A A Nash
Journal:  Virology       Date:  1990-08       Impact factor: 3.616

6.  Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection.

Authors:  G J Mertz; R Ashley; R L Burke; J Benedetti; C Critchlow; C C Jones; L Corey
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

7.  Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine.

Authors:  E N Kitces; P S Morahan; J G Tew; B K Murray
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

8.  Experimental ulcerative herpetic keratitis. IV. Preliminary observations on the efficacy of a herpes simplex subunit vaccine.

Authors:  C A Carter; C E Hartley; G R Skinner; S P Turner; D L Easty
Journal:  Br J Ophthalmol       Date:  1981-10       Impact factor: 4.638

9.  Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice.

Authors:  R J Klein; E Buimovici-Klein; H Moser; R Moucha; J Hilfenhaus
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

10.  Prepubertal vaccination of mice against experimental infection of the genital tract with type 2 herpes simplex virus.

Authors:  G R Skinner; D R Williams; A W Moles; A Sargent
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

View more
  5 in total

Review 1.  Control of STDs--the role of prophylactic vaccines against herpes simplex virus.

Authors:  L R Stanberry
Journal:  Sex Transm Infect       Date:  1998-12       Impact factor: 3.519

2.  Towards an effective genital herpes vaccine: past lessons and future prospects.

Authors:  William P Halford
Journal:  Future Virol       Date:  2007-01-01       Impact factor: 1.831

3.  Characterization and immunogenicity of a candidate subunit vaccine against varicella-zoster virus.

Authors:  J Davies; J A Hallworth; P McLeish; S Randall; B A Martin; A Buchan; G R Skinner
Journal:  Med Microbiol Immunol       Date:  1994-05       Impact factor: 3.402

Review 4.  Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.

Authors:  Michael W Ferenczy
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

5.  Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2.

Authors:  William P Halford; Joshua Geltz; Edward Gershburg
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.